

Asad Umar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5382134/publications.pdf>

Version: 2024-02-01

65
papers

6,827
citations

147801

31
h-index

98798

67
g-index

71
all docs

71
docs citations

71
times ranked

7965
citing authors

#	ARTICLE	IF	CITATIONS
1	Methylated Septin9 (<i>m</i> <i>SEPT9</i>): A Promising Blood-Based Biomarker for the Detection and Screening of Early-Onset Colorectal Cancer. <i>Cancer Research Communications</i> , 2022, 2, 90-98.	1.7	8
2	Aspirin and the Risk of Colorectal Cancer According to Genetic Susceptibility among Older Individuals. <i>Cancer Prevention Research</i> , 2022, 15, 447-454.	1.5	5
3	Role of Aspirin in Gastric Cancer Prevention. <i>Cancer Prevention Research</i> , 2022, 15, 213-215.	1.5	1
4	Redefining precision cancer prevention to promote health equity. <i>Trends in Cancer</i> , 2022, 8, 295-302.	7.4	3
5	Multi-Cancer Early Detection Tests: Current Progress and Future Perspectives. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 512-514.	2.5	11
6	Naproxen chemoprevention promotes immune activation in Lynch syndrome colorectal mucosa. <i>Gut</i> , 2021, 70, 555-566.	12.1	37
7	Effect of Aspirin on Cancer Incidence and Mortality in Older Adults. <i>Journal of the National Cancer Institute</i> , 2021, 113, 258-265.	6.3	80
8	Association of Common Use Pharmaceuticals in Reducing Risk of Esophageal Adenocarcinoma: A SEER Medicare Analysis. <i>Cancer Prevention Research</i> , 2021, 14, 195-204.	1.5	9
9	Evaluation of Aspirin Use With Cancer Incidence and Survival Among Older Adults in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. <i>JAMA Network Open</i> , 2021, 4, e2032072.	5.9	18
10	Randomized Phase II Trial of Polyphenon E versus Placebo in Patients at High Risk of Recurrent Colonic Neoplasia. <i>Cancer Prevention Research</i> , 2021, 14, 573-580.	1.5	16
11	A Phase I Trial of Berberine in Chinese with Ulcerative Colitis. <i>Cancer Prevention Research</i> , 2020, 13, 117-126.	1.5	35
12	Immuno-Interception for Patients with High-Risk Cancer. <i>Cancer Prevention Research</i> , 2020, 13, 493-496.	1.5	0
13	Early-onset colorectal cancer research: gaps and opportunities. <i>Colorectal Cancer</i> , 2020, 9, CRC34.	0.8	9
14	Efficacy of Difluoromethylornithine and Aspirin for Treatment of Adenomas and Aberrant Crypt Foci in Patients with Prior Advanced Colorectal Neoplasms. <i>Cancer Prevention Research</i> , 2019, 12, 821-830.	1.5	13
15	Association of Aspirin Use With Mortality Risk Among Older Adult Participants in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. <i>JAMA Network Open</i> , 2019, 2, e1916729.	5.9	30
16	Increasing Incidence of Colorectal Cancer in Young Adults. <i>Journal of Cancer Epidemiology</i> , 2019, 2019, 1-9.	1.1	83
17	The Making of a PreCancer Atlas: Promises, Challenges, and Opportunities. <i>Trends in Cancer</i> , 2018, 4, 523-536.	7.4	36
18	Spectral biomarkers for chemoprevention of colonic neoplasia: a placebo-controlled double-blinded trial with aspirin. <i>Gut</i> , 2017, 66, 285-292.	12.1	30

#	ARTICLE	IF	CITATIONS
19	Bioactivity of Oral Linaclotide in Human Colorectum for Cancer Chemoprevention. <i>Cancer Prevention Research</i> , 2017, 10, 345-354.	1.5	35
20	NSAIDs and EGFR Inhibitors for Duodenal Polyp Prevention. <i>JAMA Oncology</i> , 2016, 2, 1223.	7.1	0
21	Mechanisms of esophageal adenocarcinoma formation and approaches to chemopreventive intervention. <i>Seminars in Oncology</i> , 2016, 43, 78-85.	2.2	4
22	Introduction: Cancer chemoprevention and its context. <i>Seminars in Oncology</i> , 2016, 43, 19-21.	2.2	15
23	Immunologic approaches to cancer prevention—current status, challenges, and future perspectives. <i>Seminars in Oncology</i> , 2016, 43, 161-172.	2.2	35
24	Mechanisms of nonsteroidal anti-inflammatory drugs in cancer prevention. <i>Seminars in Oncology</i> , 2016, 43, 65-77.	2.2	72
25	Cancer Immunoprevention: A New Approach to Intercept Cancer Early. <i>Cancer Prevention Research</i> , 2014, 7, 1067-1071.	1.5	24
26	Future directions in cancer prevention. <i>Nature Reviews Cancer</i> , 2012, 12, 835-848.	28.4	200
27	Is 15-LOX-1 a Tumor Suppressor?. <i>Journal of the National Cancer Institute</i> , 2012, 104, 645-647.	6.3	11
28	Barrett's esophagus: natural history. <i>Annals of the New York Academy of Sciences</i> , 2011, 1232, 292-308.	3.8	11
29	Further Thoughts on Preclinical Animal Models for Cancer Prevention: When Is It Best to Start Treatment? What Are Potential Histopathologic Endpoints?. <i>Seminars in Oncology</i> , 2010, 37, 339-344.	2.2	4
30	One Year Recurrence of Aberrant Crypt Foci. <i>Cancer Prevention Research</i> , 2010, 3, 839-843.	1.5	13
31	Chemoprevention of Nonmelanoma Skin Cancer With Celecoxib: A Randomized, Double-Blind, Placebo-Controlled Trial. <i>Journal of the National Cancer Institute</i> , 2010, 102, 1835-1844.	6.3	209
32	Five-Year Efficacy and Safety Analysis of the Adenoma Prevention with Celecoxib Trial. <i>Cancer Prevention Research</i> , 2009, 2, 310-321.	1.5	176
33	A Multicenter Study of Prevalence and Risk Factors for Aberrant Crypt Foci. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 568-574.	4.4	38
34	The natural history of aberrant crypt foci. <i>Gastrointestinal Endoscopy</i> , 2008, 67, 1097-1102.	1.0	33
35	Colorectal cancer prevention: Diet, drugs, or nothing. <i>Current Colorectal Cancer Reports</i> , 2007, 3, 16-23.	0.5	2
36	Gene expression analysis of tumor infiltrating lymphocyte markers in endometrial cancers indicates no significant increases in those cases with microsatellite instability. <i>Cancer Biomarkers</i> , 2006, 2, 61-68.	1.7	2

#	ARTICLE	IF	CITATIONS
37	Lynch syndrome (HNPCC) and microsatellite instability analysis guidelines. <i>Cancer Biomarkers</i> , 2006, 2, 1-4.	1.7	3
38	Gene Expression Profiling of Microsatellite Unstable and Microsatellite Stable Endometrial Cancers Indicates Distinct Pathways of Aberrant Signaling. <i>Cancer Research</i> , 2005, 65, 5031-5037.	0.9	55
39	The Promise of Biomarkers in Colorectal Cancer Detection. <i>Disease Markers</i> , 2004, 20, 87-96.	1.3	11
40	Lynch Syndrome (HNPCC) and Microsatellite Instability. <i>Disease Markers</i> , 2004, 20, 179-180.	1.3	33
41	Serum Proteomic Profiles Suggest Celecoxib-Modulated Targets and Response Predictors. <i>Cancer Research</i> , 2004, 64, 2904-2909.	0.9	34
42	An Msh2 Point Mutation Uncouples DNA Mismatch Repair and Apoptosis. <i>Cancer Research</i> , 2004, 64, 517-522.	0.9	165
43	Modulation by celecoxib and difluoromethylornithine of the methylation of DNA and the estrogen receptor- α gene in rat colon tumors. <i>Carcinogenesis</i> , 2004, 25, 1917-1923.	2.8	39
44	Testing guidelines for hereditary non-polyposis colorectal cancer. <i>Nature Reviews Cancer</i> , 2004, 4, 153-158.	28.4	164
45	Applications of Bioinformatics in Cancer Detection: A Lexicon of Bioinformatics Terms. <i>Annals of the New York Academy of Sciences</i> , 2004, 1020, 263-276.	3.8	3
46	Zn ²⁺ -Chelating Motif-Tethered Short-Chain Fatty Acids as a Novel Class of Histone Deacetylase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 467-474.	6.4	99
47	Colorectal carcinoma in black and white race. <i>Cancer and Metastasis Reviews</i> , 2003, 22, 67-82.	5.9	54
48	Epigenetics in Cancer Prevention: Early Detection and Risk Assessment. <i>Annals of the New York Academy of Sciences</i> , 2003, 983, 1-4.	3.8	21
49	DNA Methylation as a Cancer-specific Biomarker. <i>Annals of the New York Academy of Sciences</i> , 2003, 983, 286-297.	3.8	33
50	Cyclooxygenase inhibition in cancer prevention and treatment. <i>Expert Opinion on Pharmacotherapy</i> , 2003, 4, 2193-2204.	1.8	20
51	Title is missing!. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2003, 26, S48-S57.	1.3	9
52	Non-Steroidal Anti-Inflammatory and Cyclooxygenase-2-Selective Inhibitors in Clinical Cancer Prevention Trials. , 2003, 37, 210-242.		8
53	Non-steroidal anti-inflammatory drugs (NSAIDs) for colorectal cancer prevention. <i>Cancer Chemotherapy and Biological Response Modifiers</i> , 2003, 21, 759-789.	0.5	5
54	The Role of Cyclooxygenase Inhibitors in Cancer Prevention. <i>Current Pharmaceutical Design</i> , 2002, 8, 1035-1062.	1.9	77

#	ARTICLE	IF	CITATIONS
55	Chemoprevention of colorectal carcinogenesis. <i>International Journal of Clinical Oncology</i> , 2002, 7, 2-26.	2.2	17
56	The Future of Colon Cancer Prevention. <i>Annals of the New York Academy of Sciences</i> , 2001, 952, 88-108.	3.8	33
57	Characterization of Distinct Human Endometrial Carcinoma Cell Lines Deficient in Mismatch Repair That Originated from a Single Tumor. <i>Journal of Biological Chemistry</i> , 1998, 273, 26662-26669.	3.4	29
58	Functional Overlap in Mismatch Repair by Human MSH3 and MSH6. <i>Genetics</i> , 1998, 148, 1637-1646.	2.9	130
59	Mutation in the Mismatch Repair Gene Msh6 Causes Cancer Susceptibility. <i>Cell</i> , 1997, 91, 467-477.	28.9	326
60	Meiotic Pachytene Arrest in MLH1-Deficient Mice. <i>Cell</i> , 1996, 85, 1125-1134.	28.9	528
61	Requirement for PCNA in DNA Mismatch Repair at a Step Preceding DNA Resynthesis. <i>Cell</i> , 1996, 87, 65-73.	28.9	539
62	Mutation of MSH3 in endometrial cancer and evidence for its functional role in heteroduplex repair. <i>Nature Genetics</i> , 1996, 14, 102-105.	21.4	149
63	Reciprocal homologous recombination in or near antibody VDJ genes. <i>European Journal of Immunology</i> , 1995, 25, 2392-2400.	2.9	16
64	A hPMS2 Mutant Cell Line Is Defective in Strand-specific Mismatch Repair. <i>Journal of Biological Chemistry</i> , 1995, 270, 18183-18186.	3.4	72
65	Linkage of two pseudogenes from V ^H 1 and V ^H 9 murine immunoglobulin families. <i>Molecular Immunology</i> , 1992, 29, 295-301.	2.2	8